LINCOLN PHARMA LTD Intrinsic Value

LINCOLN · Healthcare · Current price ₹614.3

Full stock page
DocStoX fair value
₹690
low confidence
Current price
₹614
Upside to fair value
+12.3%
Verdict
Fairly Valued
Quality score
4.6 / 10
Model it yourself — Intrinsic Value Calculator
Opens pre-filled with LINCOLN PHARMA LTD's latest numbers.

Is LINCOLN PHARMA LTD undervalued?

DocStoX estimates the fair value of LINCOLN PHARMA LTD at ₹690 per share, versus the current market price of ₹614. That puts the stock about +12.3% below our fair-value estimate, which we read as "Fairly Valued". Our confidence in this estimate is low.

How this fair value is calculated

This estimate blends 3 independent methods: Residual income (₹392), Relative P/E (₹1,330), Graham floor (₹611). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.

Bear, base and bull scenarios

Our scenarios span ₹392 (bear) to ₹690 (base) to ₹1,330 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.

Margin of safety

Value investors demand a margin of safety — a discount to intrinsic value that protects against being wrong. At ₹614 versus an intrinsic value of ₹690, LINCOLN PHARMA LTD currently offers +12.3% of margin.

More on LINCOLN PHARMA LTD

Fair ValueDCFValuationFinancial RatiosPeers

DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.